ECMC Trial Portfolio
Select Disease Group:
All Solid Tumours | |||||
| Project Title | Website | PI | Recruitment | Contact | |
| ACIT I: A Phase I clinical study to determine the optimal dose for the safe immune restoration and immune response of allogeneic cell immunotherapy (ACIT-1) in adult cancer patients
| ACIT-1 | Prof. D Palmer | 26 | Send E-mail | |
| Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy
| CA209-8KX | Prof. D Palmer | 0 | Send E-mail | |
| A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alteration
| RAGNAR - 42756493CAN2002 | Prof. D Palmer | 0 | Send E-mail | |
| 26 | |||||
| Back to top
| |||||
Breast | |||||
| Project Title | Website | PI | Recruitment | Contact | |
| A Modular, Multipart, Multiarm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination with Anti-cancer Treatments in Patients with Advanced Malignancies
| CT7001-001 | Prof C Palmieri | 0 | Send E-mail | |
| A Phase I, Multicenter, Open-Label Preoperative, Short-Term Window Study of GDC-9545 in Postmenopausal Women with Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer
| GO40987 - GDC-9545 | Prof C Palmieri | 7 | Send E-mail | |
| A multiple parallel cohort, non-randomised, open label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening
| plasmaMATCH | Prof C Palmieri | 7 | Send E-mail | |
| 7 | |||||
| Back to top
| |||||
Haematology | |||||
| Project Title | Website | PI | Recruitment | Contact | |
| A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination with Polatuzumab Vedotin and Lenalidomide in Patients with Relapsed or Refractory Follicular or Refractory Follicular or Diffuse Large B-Cell Lymphoma
| HARMONY | Dr. A. Arumainathan | 1 | Send E-mail | |
| Treatment of steroid refractory gastro-intestinal acute graft-versus-Host disEase afteR AllogeneiC hematopoietic stem celL transplantation with faEcal microbiota transfer (HERACLES)
| HERACLES | Dr. A. Patel | 0 | Send E-mail | |
| A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Haematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients with Myelofibrosis)
| MANIFEST | Dr. N. Butt | 0 | Send E-mail | |
| A phase Ib study to assess the safety and tolerability of oral Ruxolitinib in combination with 5-azacitidine in patients with advanced phase myeloproliferative neoplasms (MPN), including myelodysplastic syndromes (MDS) or acute myeloid leukaemia (AML) arising from MPN.
| PHAZAR | Dr. A. Patel | 1 | Send E-mail | |
| Risk-stratified sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-novo post-transplant Lymphoproliferative disorder (PTLD)
| TIDaL | Dr A. Arumainathan | 2 | Send E-mail | |
| 5 | |||||
| Back to top
| |||||
Head & Neck | |||||
| Project Title | Website | PI | Recruitment | Contact | |
| Cambridge Brain Mets Trial 1: A proof of principle phase 1b / randomised phase 2 study of afatinib penetration into cerebral metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy
| CamBMT1 | Dr B Haylock | 0 | Send E-mail | |
| NICO - CA209-891: Neoadjuvant and adjuvant nivolumab as Immune Checkpoint inhibition in Oral cavity cancer
| NICO | Dr A Haridass | 0 | Send E-mail | |
| An Open-Label, Multicenter, Phase 1 Study of RP2 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors
| REPLIMUNE 2 | Dr J Sacco | 1 | Send E-mail | |
| 1 | |||||
| Back to top
| |||||
HPB / Upper GI | |||||
| Project Title | Website | PI | Recruitment | Contact | |
| OUTREACH: A First-in-Human, multi-centre, open-label, Phase 1 clinical study with RNA oligonucleotide drug MTL-CEBPA to investigate its safety and tolerability in patients with advanced liver cancer (OUTREACH)
| OUTREACH / CANC 4818 | Prof. D Palmer | 6 | Send E-mail | |
| A phase II multicenter, single arm study of oral BGJ398 in adult patients with advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions or other FGFR genetic alterations who failed or are intolerant to platinum-based chemotherapy
| QED BGJ398 | Prof. D Palmer | 0 | Send E-mail | |
| 6 | |||||
| Back to top
| |||||
Lung | |||||
| Project Title | Website | PI | Recruitment | Contact | |
| The Cancer Research UK Stratified Medicine Programme: Pilot Study
| CR UK Stratified Medicine Pilot study | Dr. Carles Escriu | 72 | Send E-mail | |
| National Lung Matrix Trial: Multi-drug, genetic marker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer
| National Lung Matrix Trial | Dr. Carles Escriu | 1 | Send E-mail | |
| 73 | |||||
| Back to top
| |||||
Melanoma | |||||
| Project Title | Website | PI | Recruitment | Contact | |
| A parallel arm, biomarker driven, phase II feasibility trial to determine the role of circulating tumour DNA in guiding a switch between targeted therapy and immune therapy in patients with advanced cutaneous melanoma
| Circulating tumour DNA guided therapy switch (CAcTUS) | Dr. Shien Chow | 1 | Send E-mail | |
| An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with Immune Checkpoint Blockade or Other Standard of Care Regimens in Patients with Solid Tumors
| REPLIMUNE 1 | Dr J Sacco | 5 | Send E-mail | |
| 6 | |||||
| Back to top
| |||||
Tweets by livecmc
